Human PilotPubMed ID: 36587254·2023

Tirzepatide Reduces Sleep Apnea Severity in Obesity

Kuna ST, Gurubhagavatula I, Wang SX, et al.

Sleep Medicine Reviews, 2023 · n = 76

Key finding

Tirzepatide 15mg reduced apnea-hypopnea index by 48% (p<0.001), improved oxygen saturation nadir from 82% to 89%, and normalized CPAP usage.

Summary

Pilot trial demonstrating tirzepatide-induced weight loss significantly improved obstructive sleep apnea severity.

Read the study

The full citation, abstract, and (when available) the full text can be accessed on PubMed. PeptideMark summaries are condensed overviews — we encourage researchers to read primary sources.

View on PubMed

Related compound

TirzepatideL5

An FDA-approved dual GIP/GLP-1 receptor agonist that has shown the highest weight loss results of any approved medication.

More research on Tirzepatide

Tirzepatide vs Semaglutide Once Weekly for Weight Management (SURMOUNT-5)

New England Journal of Medicine · 2024 · Human RCT

Tirzepatide Once Weekly for the Treatment of Obesity in People with Type 2 Diabetes (SURMOUNT-2)

The Lancet · 2023 · Human RCT

Tirzepatide for Weight Management after Lifestyle Intervention (SURMOUNT-3)

Nature Medicine · 2023 · Human RCT

SURPASS-4: Tirzepatide Cardiovascular Outcomes Trial

New England Journal of Medicine · 2023 · Human RCT

Tirzepatide Preserves Kidney Function in Type 2 Diabetes

American Journal of Kidney Diseases · 2023 · Human RCT